Levothyroxine Sodium Tablets, USP, Thyro-Tabs, 150mcg, 1000 Tablets
Recalled by Alvogen, Inc
Class II — moderate
Using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.
Alvogen, Inc has recalled Levothyroxine Sodium Tablets, USP, Thyro-Tabs, 150mcg, 1000 Tablets, according to data published by the U.S. Food and Drug Administration (FDA). The recall was reported on January 21, 2026 and was initiated on December 31, 2025. It is classified as a Class II recall, which means using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.
Below is a plain-English summary of what was recalled, why it was recalled, how to tell whether you have the affected product, and what steps you can take. For the complete and most current details, you can view the FDA record linked further down this page.
What was recalled?
This recall covers Levothyroxine Sodium Tablets, USP, Thyro-Tabs, 150mcg, 1000 Tablets. The company behind the recall is Alvogen, Inc, based in Morristown, NJ. The FDA describes the product as: “Levothyroxine Sodium Tablets, USP, Thyro-Tabs, 150mcg, 1000 Tablets, Rx only, Manufactured by: LLOYD, Inc., Shenandoah, IA, 51601 USA, Distributed by: Alvogen, Inc., Pine Brook, NJ 07058 USA, NDC: 47781-662-10.”
Why was Levothyroxine Sodium Tablets, USP, Thyro-Tabs, 150mcg, 1000 Tablets recalled?
According to the FDA, the stated reason for the recall is: “Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.”
What should you do?
If you think you may have bought Levothyroxine Sodium Tablets, USP, Thyro-Tabs, 150mcg, 1000 Tablets, compare it against the product description and identifying codes (Lot # MHA21825, Exp Date: December 31, 2027) before using it. This recall is currently listed as ongoing.
The general guidance for a matching product is to stop using it and follow the instructions in the official FDA recall notice, which may include a repair, replacement, refund, or safe disposal. When in doubt, contact Alvogen, Inc or your local health authority.
About this recall
This recall was distributed in NJ. RecallRadar summarizes recall information from public FDA data to make it easier to understand. We are an independent service and are not affiliated with the FDA or any government agency, so please always refer to the official source for the authoritative record — and note the “last synced” date shown on this page, since recall details can change over time.
Full recall details
- Status
- Ongoing
- Date reported
- January 21, 2026
- Recall started
- December 31, 2025
- Distributed in
- NJ
What you can do
Check whether any product you have matches the description and codes above. If it does, stop using it and follow the instructions in the official recall notice. When in doubt, contact the company or your local health authority.
Quick answers
Why was Levothyroxine Sodium Tablets, USP, Thyro-Tabs, 150mcg, 1000 Tablets recalled?+
According to the FDA: Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets…
How serious is this recall?+
Class II — moderate. Using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.
What should I do if I have Levothyroxine Sodium Tablets, USP, Thyro-Tabs, 150mcg, 1000 Tablets?+
Compare your product against the description and identifying codes on this page. If it matches, stop using it and follow the instructions in the official recall notice — this usually means returning it for a refund or discarding it. When in doubt, contact the company or your local health authority.
Opens the U.S. Food and Drug Administration (FDA) data for this recall.
Recall number: D-0259-2026. Information last synced from the FDA on July 5, 2026.